HighTower Advisors
NUVB icon

HighTower Advisors’s Nuvation Bio NUVB Stock Holding History

HighTower Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Sell
19,249
-8,949
-32% -$43.7K ﹤0.01% 3646
2026
Q1 		$121K Buy
28,198
+5,741
+26% +$32K ﹤0.01% 3600
2025
Q4 		$201K Buy
22,457
+2,007
+10% +$12.4K ﹤0.01% 3374
2025
Q3 		$75.7K Buy
20,450
+10,000
+96% +$27.3K ﹤0.01% 3580
2025
Q2 		$20.4K Buy
+10,450
New +$21.8K ﹤0.01% 3615

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HighTower Advisors's NUVB Position: Q2 2026 in Review

HighTower Advisors reduced its Nuvation Bio (NUVB) stake by 32% in Q2 2026, selling an estimated $43.7K and leaving 19,249 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #3646.

HighTower Advisors first reported a position in NUVB in Q2 2025 and has held it in 5 quarters since. The position peaked at $201K in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • HighTower Advisors held 19,249 shares of Nuvation Bio worth $109K as of Q2 2026.
  • HighTower Advisors sold 8,949 Nuvation Bio shares in Q2 2026, an estimated $43.7K.
  • Nuvation Bio made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3646 holding.
  • HighTower Advisors first reported a position in Nuvation Bio in Q2 2025 and has held it in 5 quarters since.
  • HighTower Advisors's Nuvation Bio position peaked at $201K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.